Loading…
Edurant is a brand name for Rilpivirine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: EDURANT, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and paediatric patients weighing at least 25 kg without known mutations associated with resistance to the non-nucleoside reverse transcriptase…
Verbatim from this product's EMA label. Tap a section to expand.
Therapy should be initiated by a physician experienced in the management of HIV infection. Posology The recommended dose of EDURANT in adult and paediatric patients weighing at least 25 kg is one 25 mg tablet taken once daily. 2). 5 mg dispersible tablets for paediatric patients aged 2 to less than 18 years weighing at least 14 kg and less than 25 kg.
The recommended dosage of EDURANT in these paediatric patients is based on body weight. 5 mg dispersible tablets was observed, therefore they are not interchangeable. Dose adjustment For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) taken once daily.
5). Missed dose If the patient misses a dose of EDURANT within 12 hours of the time it is usually taken, the patient must take the medicine with a meal as soon as possible and resume the normal dosing schedule. If a 3 patient misses a dose of EDURANT by more than 12 hours, the patient should not take the missed dose, but resume the usual dosing schedule.
If a patient vomits within 4 hours of taking the medicine, another EDURANT tablet should be taken with a meal. If a patient vomits more than 4 hours after taking the medicine, the patient does not need to take another dose of EDURANT until the next regularly scheduled dose.
Special populations Elderly There is limited information regarding the use of EDURANT in patients > 65 years of age. 2). EDURANT should be used with caution in this population. Renal impairment EDURANT has mainly been studied in patients with normal renal function.
No dose adjustment of rilpivirine is required in patients with mild or moderate renal impairment. In patients with severe renal impairment or end-stage renal disease, rilpivirine should be used with caution. 2). 8). Hepatic impairment There is limited information regarding the use of EDURANT in patients with mild or moderate hepatic impairment (Child-Pugh score A or B).
No dose adjustment of EDURANT is required in patients with mild or moderate hepatic impairment. EDURANT should be used with caution in patients with moderate hepatic impairment. EDURANT has not been studied in patients with severe hepatic impairment (Child-Pugh score C).
2). Paediatric population The safety and efficacy of EDURANT in children less than 2 years or weighing less than 14 kg have not been established. No data are available. Pregnancy Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely.
1). 0%). 0%) patients receiving rilpivirine. 1 weeks, respectively. Most ADRs occurred in the first 48 weeks of treatment. 1%). Tabulated summary of adverse reactions ADRs reported in adult patients treated with rilpivirine are summarised in Table 2.
The ADRs are listed by system organ class (SOC) and frequency. Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100). Within each frequency grouping, ADRs are presented in order of decreasing frequency.
Table 2:
ADRs reported in antiretroviral treatment-naïve HIV-1 infected adult patients treated with Rilpivirine (pooled data from the week 96 analysis of the phase 3 ECHO and THRIVE trials) N=686 System Organ Class (SOC) Frequency Category ADRs (Rilpivirine + BR) Blood and lymphatic system disorders common decreased white blood cell count decreased haemoglobin decreased platelet count Immune system disorders uncommon immune reactivation syndrome Metabolism and nutrition disorders very common increased total cholesterol (fasted) increased LDL cholesterol (fasted) common decreased appetite increased triglycerides (fasted) Psychiatric disorders very common insomnia common abnormal dreams depression sleep disorders depressed mood Nervous system disorders very common headache dizziness common somnolence Gastrointestinal disorders very common nausea increased pancreatic amylase 12 common abdominal pain vomiting increased lipase abdominal discomfort dry mouth Hepatobiliary disorders very common increased transaminases common increased bilirubin Skin and subcutaneous tissue disorders common rash General disorders and administration site conditions common fatigue BR=background regimen N=number of subjects Laboratory abnormalities In the rilpivirine arm in the week 96 analysis of the phase 3 ECHO and THRIVE trials, mean change from baseline in total cholesterol (fasted) was 5 mg/dl, in HDL cholesterol (fasted) 4 mg/dl, in LDL cholesterol (fasted) 1 mg/dl, and in triglycerides (fasted) -7 mg/dl.
Virologic failure and development of resistance EDURANT has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy. 1 should only guide the use of EDURANT in the treatment-naïve population.
6% with efavirenz). 1). Patients with a baseline viral load > 100,000 HIV-1 RNA copies/ml who experienced virologic failure exhibited a higher rate of treatment-emergent resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class.
1). Findings in adolescents and paediatric patients in trial TMC278-C213 were generally in line with these data. 1). Only patients deemed likely to have good adherence to antiretroviral therapy should be treated with rilpivirine, as suboptimal adherence can lead to development of resistance and the loss of future treatment options.
1). 2). EDURANT at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc. EDURANT should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
Immune reactivation syndrome In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions or aggravation of symptoms.
Typically, such reactions have been observed within the first weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and Pneumocystis jiroveci pneumonia.
Any inflammatory symptoms should be evaluated and treatment instituted when necessary. 8). 5 Pregnancy EDURANT should be used during pregnancy only if the potential benefit justifies the potential risk. Lower exposures of rilpivirine were observed when rilpivirine 25 mg once daily was taken during pregnancy.
1. 5): - the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin - the antimycobacterials rifampicin, rifapentine 4 - proton pump inhibitors, such as omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole - the systemic glucocorticoid dexamethasone, except as a single dose treatment - St John’s wort (Hypericum perforatum).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Rilpivirine in European Union.
Know a brand we are missing in European Union? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2). 2). It is recommended that the film-coated tablet be swallowed whole with water and not be chewed or crushed.
Description of selected adverse reactions Immune reactivation syndrome In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.
4). 1). 5 weeks. There were no patients who discontinued treatment due to ADRs. No new ADRs were identified compared to those seen in adults. Most ADRs were grade 1 or 2. 1%). No grade 3-4 laboratory abnormalities for AST/ALT or grade 3-4 ADRs of transaminase increased were reported.
There were no new safety concerns identified in the week 240 analysis of the TMC278-C213 Cohort 1 trial in adolescents. 1). 5 (range 35 to 218) weeks. All ADRs were mild or moderate. 1%). There were no patients who discontinued treatment due to ADRs.
No new ADRs were identified compared to those seen in adults. 1). The median duration of exposure for patients in the week 48 analysis was […]
2). Alternatively, switching to another ART regimen could be considered. Important information about some of the ingredients of EDURANT EDURANT contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.